TY  - SOUND
AU  - Shakir,Saad
TI  - The Oxford/AstraZeneca COVID-19 vaccine trial: adverse patient event reports 
T2  - Interviews on Covid-19,
PY  - 2020///
CY  - London
PB  - Henry Stewart Talks
KW  - AstraZeneca (Firm)
KW  - University of Oxford
KW  - Clinical trials
KW  - COVID-19 (Disease)
KW  - Vaccination
KW  - Vaccines
KW  - Development
KW  - ChAdOx1 COVID-19 vaccine
KW  - Clinical Trials as Topic
KW  - COVID-19 Vaccines
KW  - adverse effects
KW  - COVID-19
KW  - prevention & control
KW  - Pharmacovigilance
KW  - Research Design
KW  - SARS-CoV-2
N1  - Audio interview; Title from title frames; Contents: Mode of action of the Oxford/AstraZeneca RNA vaccine -- Two potential adverse events reported in patients enrolled in the vaccine's phase 3 trial -- Steps undertaken to determine possible causality between the adverse events and the vaccine -- Current status of the trial -- Please note that since the recording of this interview it was determined that "The serious adverse events observed during the trial in these study groups were judged to be unrelated to the study vaccines and occurred at frequencies expected for these conditions in the general population. None of the participants included in this report had any suspected unexpected serious adverse reactions." (Ramasamy et al., The Lancet, November 18, 2020, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext); Access restricted to subscribers
UR  - https://hstalks.com/bs/4463/
UR  - https://hstalks.com/bs/p/1060/
ER  -